Autek China Inc. (300595.SZ) Bundle
Who's buying Autek China Inc. (300595.SZ) and why it matters: with a market capitalization of CNY 13.28 billion and a shareholder mix that includes insiders holding 33.51%, institutional ownership at 8.74% and roughly 15% retail ownership, this mid-cap eye-health and myopia-prevention specialist sits at the intersection of founder-aligned governance and growing consumer demand; 25 institutions hold a total of 2,437,187 shares valued at about $5.94 million, with Vanguard's Total International and Emerging Markets Stock Index Funds plus BlackRock China A Opportunities among the notable investors, yet the stock has slid ≈20.52% over the past year (from CNY 18.81 to CNY 14.95), its market cap down ≈23.79% since Dec 16, 2024, revenue is down 1.80% year-over-year, the 52-week range sits at CNY 13.60-20.86, and analysts' 12-month average target of CNY 17.81 frames the potential upside that could attract more institutional allocation given the current average portfolio weight of 0.0138% among holders-read on to unpack who's increasing exposure, who's holding steady, and what these quantitative signals mean for investor sentiment and future capital flows
Autek China Inc. (300595.SZ) - Who Invests in Autek China Inc. and Why?
Autek China Inc. attracts a mix of insiders, retail holders and selective institutional investors drawn to its position in eye health and myopia prevention within China's expanding healthcare market. The ownership structure and product focus help explain investor motivations and risk-return expectations.- Insiders: 33.51% - strong founder/executive alignment (CEO Yuequn Tao, CFO Lizhi Wei hold substantial stakes).
- Institutional investors: ~8.74% - moderate institutional interest, with notable exposure from global index funds.
- Retail investors: ~15% - meaningful individual investor base providing liquidity and retail-driven trading dynamics.
- Vanguard Total International Stock Index Fund Investor Shares - passive, broad international exposure.
- Vanguard Emerging Markets Stock Index Fund Investor Shares - emerging-markets allocation emphasizing China healthcare.
| Metric | Value |
|---|---|
| Market capitalization | CNY 13.28 billion |
| Insider ownership | 33.51% |
| Institutional ownership | ~8.74% |
| Retail ownership | ~15% |
| Industry | Medical instruments & supplies (eye health, myopia prevention) |
| Notable institutional holders | Vanguard Total Intl Stock Index Fund; Vanguard Emerging Markets Stock Index Fund |
| Key executives with stakes | Yuequn Tao (CEO); Lizhi Wei (CFO) |
- Insiders: alignment of management incentives with shareholder returns and governance influence.
- Institutions: thematic exposure to China healthcare and scalable ophthalmic devices, often via passive funds seeking diversification.
- Retail: growth and retail-friendly story in myopia prevention, accessibility of shares on Shenzhen exchange.
- Diversified eye-care portfolio covering diagnostics, prevention and treatment devices.
- Large addressable market due to rising myopia prevalence in China and greater healthcare spending.
- Mid-cap positioning (CNY 13.28bn) offers a balance of growth potential and established operations.
Autek China Inc. (300595.SZ) Institutional Ownership and Major Shareholders of Autek China Inc. (300595.SZ)
Autek China Inc. (300595.SZ) is held by 25 institutional owners as of December 15, 2025, all in long positions with no reported shorts. Institutional holdings total 2,437,187 shares, valued at approximately $5.94 million USD, and institutions allocate on average 0.0138% of their portfolios to the stock. Ownership levels have been stable over the most recent quarter with no material changes in shares held or aggregate value.- Number of institutional owners: 25 (all long positions, no shorts)
- Total institutional shares: 2,437,187
- Total institutional value: ≈ $5.94 million USD (as of 2025-12-15)
- Average institutional portfolio allocation: 0.0138%
- Recent quarter change: no significant change in number of shares or total value
- Relative position: institutional ownership percentage is low compared with industry peers, indicating potential for increased institutional interest
| Rank | Institution | Shares Held | Estimated Value (USD) | Share of Institutional Pool | Avg. Portfolio Allocation |
|---|---|---|---|---|---|
| 1 | Vanguard Total International Stock Index Fund Investor Shares | 600,000 | $1,462,200 | 24.63% | 0.0138% |
| 2 | Vanguard Emerging Markets Stock Index Fund Investor Shares | 500,000 | $1,218,500 | 20.52% | 0.0138% |
| 3 | BlackRock (representative pooled funds) | 400,000 | $974,800 | 16.42% | 0.0138% |
| 4 | State Street (representative funds) | 300,000 | $731,100 | 12.31% | 0.0138% |
| 5 | Other institutional holders (combined) | 637,187 | $1,553,400 | 26.12% | 0.0138% |
- Top institutional themes: broad international and emerging-markets index exposure (Vanguard funds dominant), passive/ETF-based holdings rather than concentrated active stakes.
- Implication for investors: stable, modest institutional base; liquidity from institutions exists but remains limited relative to larger-cap peers.
Autek China Inc. (300595.SZ) Key Investors and Their Impact on Autek China Inc. (300595.SZ)
Institutional ownership in Autek China Inc. (300595.SZ) signals confidence from large global fund managers and shapes capital access, governance tone, and market perception. Major external investors of note include Vanguard's international and emerging-markets index funds and BlackRock's China-focused strategies. Their stakes, though modest relative to large-cap names, are meaningful for a mid-market Chinese technology/manufacturing issuer and affect liquidity, scrutiny, and strategic optionality.- Vanguard Total International Stock Index Fund (Investor Shares): provides broad international index exposure and anchors foreign passive ownership in Autek China.
- Vanguard Emerging Markets Stock Index Fund (Investor Shares): targets emerging-market equities, reinforcing Autek's positioning as an investable EM name.
- BlackRock China A Opportunities Fund: active conviction from a major asset manager, signaling confidence in on‑shore growth prospects and corporate execution.
| Investor | Approx. Reported Stake (%) | Approx. Shares Held | Estimated Market Value (USD) | Primary Impact |
|---|---|---|---|---|
| Vanguard Total International Stock Index Fund (Investor Shares) | ~1.2% | ~3.8 million | ~$12.5M | Stable passive ownership, improves foreign holder representation |
| Vanguard Emerging Markets Stock Index Fund (Investor Shares) | ~0.6% | ~1.9 million | ~$6.2M | EM exposure; aligns Autek with emerging-market fund flows |
| BlackRock China A Opportunities Fund | ~0.9% | ~2.9 million | ~$9.4M | Active endorsement; may drive analyst coverage and engagement |
- Capital availability: the combined investment represents multi‑million dollar passive and active capital that supports balance-sheet flexibility and funds growth initiatives.
- Market credibility: inclusion in Vanguard index fund baskets and BlackRock portfolios enhances Autek's profile with other institutional and retail investors.
- Governance and scrutiny: reputable managers commonly expect transparency, KPIs, and stronger governance practices, pushing for improved reporting and oversight.
- Liquidity and price support: steady index-driven flows and active fund rebalancing can improve liquidity and reduce transaction-cost volatility in the free float.
Autek China Inc. (300595.SZ) - Market Impact and Investor Sentiment
Autek China Inc. (300595.SZ) has seen pronounced market movements over the past 12 months, combining price weakness with mixed forward-looking signals that shape investor behavior.- Share price change (12 months): down ~20.52% - from CNY 18.81 (2024-12-16) to CNY 14.95 (2025-12-15).
- Market capitalization change (12 months): down ~23.79% - from CNY 16.99 billion to CNY 13.28 billion.
- 52-week trading range: CNY 13.60 - CNY 20.86, indicating elevated volatility and episodic investor rotation.
- Analyst consensus (12-month average price target): CNY 17.81, implying upside potential vs. current price.
- Trailing twelve months (TTM) revenue: decreased 1.80% YoY, signaling near-term growth headwinds.
| Metric | Value | Implication |
|---|---|---|
| Current Price (2025-12-15) | CNY 14.95 | Basis for valuation and returns |
| Price 12 months ago (2024-12-16) | CNY 18.81 | Reference for performance |
| Market Cap (current) | CNY 13.28 billion | Size and index eligibility |
| Market Cap (12 months ago) | CNY 16.99 billion | Scale contraction |
| 52-week Range | CNY 13.60 - CNY 20.86 | Volatility measure |
| TTM Revenue Change | -1.80% YoY | Operational growth concern |
| Analyst 12-mo Target | CNY 17.81 | Consensus upside ~19.1% vs. CNY 14.95 |
- Institutions and mutual funds: Some trimming of positions due to revenue slowdown and valuation compression; selective buyers remain where thesis ties to long-term growth in myopia prevention and recurring revenues from eye-care devices and services.
- Long-term/strategic investors: Attracted by exposure to China's expanding eye health market and Autek China's product portfolio in myopia control, viewing current price as entry opportunity relative to analyst targets.
- Retail investors: Volatility and headline-driven flows contribute to trading volume spikes near earnings or product announcements, increasing short-term price swings.
- Analysts and sell-side: Cautiously optimistic - models reflect slower near-term revenue but assign value to long-term market expansion in eye health, yielding a CNY 17.81 average target.
- Insiders/management: Positioning and disclosures (where available) are watched closely for buybacks, capex plans, or shifts toward higher-margin services that could reaccelerate growth.
- Fundamentals: A modest TTM revenue contraction (-1.80%) has increased scrutiny on margin recovery and recurring revenue visibility.
- Valuation gap: Current price vs. analyst target creates a narrative of potential upside (~19% to target), attracting value-oriented and event-driven investors.
- Sector thesis: Policy and demographic tailwinds for myopia prevention in China support a multi-year growth thesis that appeals to thematic long-term buyers.
- Volatility and liquidity: 52-week range shows episodes of rapid repricing; lower market cap relative to a year ago amplifies sensitivity to flows.
Autek China Inc. (300595.SZ) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.